Imbruvica 140 mg Alternative – Ibrucor (Ibrutinib) 140 mg Capsule | Beacon Pharmaceuticals
Iressa 250 mg Alternative – Geficent (Gefitinib) 250 mg Tablet | Incepta Pharmaceuticals
Geficent 250 mg (Gefitinib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Iressa (AstraZeneca).
Pack: 10 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Iressa 250 mg Alternative – Gefinix (Gefitinib) 250 mg Tablet | Beacon Pharmaceuticals
Jakafi / Jakavi 10 mg Alternative – Rulicent (Ruxolitinib) 10 mg Tablet | Incepta Pharmaceuticals
Rulicent 10 mg (Ruxolitinib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Jakafi / Jakavi (Incyte / Novartis).
Pack: 10 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Jakafi / Jakavi 5 mg Alternative – Rulicent (Ruxolitinib) 5 mg Tablet | Incepta Pharmaceuticals
Rulicent 5 mg (Ruxolitinib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Jakafi / Jakavi (Incyte / Novartis).
Pack: 14 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Kisqali 200 mg Alternative – Ribolib (Ribociclib) 200 mg Tablet | Beacon Pharmaceuticals
Kisqali 200 mg Alternative – Riboxen (Ribociclib) 200 mg Tablet | Everest Pharmaceuticals
Riboxen 200 mg (Ribociclib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Kisqali (Novartis). It belongs to the CDK4/6 inhibitor class and is used in selected HR-positive, HER2-negative breast cancer regimens.
Active ingredient: Ribociclib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lenvima 10 mg Alternative – Lenva (Lenvatinib) 10 mg Capsule | Beacon Pharmaceuticals
Lenvima 10 mg Alternative – Lenvaxen (Lenvatinib) 10 mg Capsule | Everest Pharmaceuticals
Lenvaxen 10 mg (Lenvatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lenvima (Eisai). It belongs to the multikinase inhibitor class and is used in selected thyroid, renal, liver and endometrial cancer regimens.
Active ingredient: Lenvatinib
Strength: 10 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lenvima 4 mg Alternative – Lenva (Lenvatinib) 4 mg Capsule | Beacon Pharmaceuticals
Lenvima 4 mg Alternative – Lenvaxen (Lenvatinib) 4 mg Capsule | Everest Pharmaceuticals
Lenvaxen 4 mg (Lenvatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lenvima (Eisai). It belongs to the multikinase inhibitor class and is used in selected thyroid, renal, liver and endometrial cancer regimens.
Active ingredient: Lenvatinib
Strength: 4 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lonsurf 15 mg / 6.14 mg Alternative – Trifluxen (Trifluridine 15 mg + Tipiracil 6.14 mg) 15 mg / 6.14 mg Tablet | Everest Pharmaceuticals
Trifluxen 15 mg / 6.14 mg (Trifluridine 15 mg + Tipiracil 6.14 mg) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lonsurf (Taiho Oncology). It belongs to the trifluridine/tipiracil combination class and is used in selected previously treated metastatic colorectal cancer and other authorized settings.
Active ingredient: Trifluridine 15 mg + Tipiracil 6.14 mg
Strength: 15 mg / 6.14 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.